Previous 10 | Next 10 |
home / stock / nvo / nvo articles
In response to growing reports of patient harm caused by counterfeit versions of its popular diabetes drug, Ozempic (semaglutide), Novo Nordis...
Novo Nordisk A/S’s (NYSE:NVO) head of development, Martin Holst Lange, expressed strong confidence in the drugmaker’s ability...
Retail traders have been observed to be selling off their shares in the ‘Magnificent Seven’ tech stocks, with a noticeable shift toward...
Thursday, Evernorth Health Services, a subsidiary of Cigna Group (NYSE:CI) introduced a financial guarantee within its EncircleRx pr...
U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday. Shares of American Eagle Outfitters, Inc. (NYSE: AEO) ...
Thursday, Novo Nordisk A/S (NYSE:NVO) is holding its Capital Markets Day. Its executive management and other members of senior management...
Ozempic maker Novo Nordisk (NYSE:NVO), a Danish pharmaceutical company, is set to launch its weight-loss drug, Wegovy, in Japan. This move is in re...
The weekly injection of semaglutide has proven to be both safe and effective, reducing liver fat in individuals with HIV and fatty liver disease, a...
Eli Lilly (NYSE:LLY) is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...